Vitamin D supplementation and cancer incidence and mortality: VITAL randomized controlled trial
Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE
Published in New England Journal of Medicine
Methodology
Randomized double-blind placebo-controlled trial of vitamin D3 2000 IU/day in 25,871 adults over a median 5.3 years, with cancer incidence and mortality endpoints.
Key Findings
Vitamin D did not lower invasive cancer incidence, though secondary analyses suggested reduced cancer death with longer follow-up.
Conclusions
Large null trial for cancer incidence; possible mortality signal only.
Limitations
Largely vitamin D replete population at baseline.
Supplements Studied
Vitamin D did not lower invasive cancer incidence over a median 5.3 years
Outcomes Measured
Vitamin D did not lower invasive cancer incidence, though secondary analyses suggested reduced cancer death with longer follow-up
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.